Industries BiotechnologyHealth CarePharmaceuticalHeadquarters Regions Greater San Diego Area, West Coast, Western US Founded Date Jul 16, 1993 Founders Mark R. Brann Operating Status Active Last Funding Type Post-IPO Equity Also Known As Receptor Technologies Legal Name ACADIA Pharmaceuticals Inc.
Stock Symbol NASDAQ:ACAD Company Type For Profit
Contact Email info@acadia-pharm.com Phone Number (858) 558-2871
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: Acadia Pharmaceuticals AB based in Malmo, Sweden and Acadia Pharmaceuticals A/S based in Denmark. The
Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study.